Dyne Therapeutics
94 hedge funds and large institutions have $457M invested in Dyne Therapeutics in 2022 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 25 increasing their positions, 32 reducing their positions, and 10 closing their positions.
700% more call options, than puts
Call options by funds: $8K | Put options by funds: $1K
10% more first-time investments, than exits
New positions opened: 11 | Existing positions closed: 10
1% more funds holding
Funds holding: 93 → 94 (+1)
0.32% less ownership
Funds ownership: 92.75% → 92.43% (-0.32%)
20% less capital invested
Capital invested by funds: $568M → $457M (-$111M)
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
22% less repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 32
Top Buyers
Top Sellers
DYN Hedge Fund Activity: Q1 2022 in Review
94 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q1 2022, worth a combined $457M — down 20% from $568M a quarter earlier.
Buyers outnumbered sellers: 11 funds opened new DYN positions and 10 closed out — a net gain of 1 holder — while 25 added to existing stakes and 32 trimmed.
The largest buyer was Deep Track Capital, adding an estimated $10.3M. The largest seller was Wellington Management Group, cutting an estimated $14.2M.
- 94 institutional investors held Dyne Therapeutics (DYN) as of Q1 2022, up from 93 in Q4 2021.
- Funds reported $457M of Dyne Therapeutics stock for Q1 2022, down 20% quarter-over-quarter.
- 11 funds opened new Dyne Therapeutics positions in Q1 2022 and 10 closed out, a net change of +1 holder.
- The largest Dyne Therapeutics buyer in Q1 2022 was Deep Track Capital, an estimated $10.3M added.
- The largest Dyne Therapeutics seller in Q1 2022 was Wellington Management Group, an estimated $14.2M sold.
Based on aggregated 13F filings for Q1 2022.